and vasculogenesis is the proliferation of endothelial cells. Two polypeptide growth factors have been identified as mitogens specific for endothelial cells, vascular endothelial growth factor (VEGF, also called vascular permeability factor, VPF)2 (1-4) and placenta growth factor (P1GF) (5). VEGF and P1GF are structurally related to the a and t3 chains of platelet-derived growth factor (PDGF) (1, 2), a mitogen for mesenchymal cells (6). These four genes belong to the same family and share a conserved motif, including eight conserved cystemne residues in the putative receptor binding domain (7). Recently, two additional members in this family, VEGF-B and VEGF-related protein (VRP), were identified to be mitogens for vascular endothelial cells (8-10). Similar to the PDGF a chain, both VEGF and P1GF are expressed as alternatively spliced forms (3, [11] [12] [13] . Different isoforms of VEGF and P1GF are named according to the number of amino acid residues as mature proteins, e.g., VEGF2O6 and P1GF152. The alternative splicing generates polypeptides with similar biological activity, but dramatically different secretion patterns and abilities to bind to hepann (8, 11) . Similar to the a and chains of PDGF, VEGF, and P1GF, each exist as homo-and heterodimers (5, 13, 14) and bind to receptors, eliciting intrinsic tyrosmne kinase activity (15) (16) (17) (18) (19) .
The receptor tyrosine kinase, KDR/Flk-1, has been identified to be the functional receptor for VEGF (15, 19, 20) . VEGF and P1GF both bind to and activate the Flt-1 receptor tyrosine kinase (21) . Recently, flt-4 tyrosine kinase receptor has been shown to be the receptor for VRP and VEGF-C, which is identical to \TRP except it is 69 amino acids shorter at the amino terminus (8, 9). Targeted disruption of flk-1, flt-2, and VEGF genes demonstrates their importance in blood vessel formation at different levels (22) (23) (24) (25) .
The difference in their phenotypes indicates the requirement of multiple regulators for blood vessel formation.
We report here the identification by high throughput sequencing of VEGF-2, which is identical to VRP except for one amino acid residue within the signal peptide. We Northern hybridization analysis was performed in human tissues and primary cells. As shown in Fig. 2A , B, the mRNA of VEGF-2 was preferentially expressed in several highly vascularized tissues including the heart, lung, placenta, and skeletal muscle. Its expression is also high in spleen, bone marrow, fetal lung, fetal kidney. In primary cultured cells, the expression of VEGF-2 mRNA is abundant in vascular smooth muscle cells and dermal fibroblast cells (Fig. 2C) To analyze the biochemical and biological properties of VEGF-2, it was expressed and purified using the baculovirus expression vector system (BEVS). A.s shown in Fig. 4A , 52 kDa, 30 kDa, and 27 kDa proteins were secreted by cells infected by recombinant VEGF-2 baculovirus, but not from cells infected by nonrecombinant baculovirus. As in mammalian cells, only a protein with a slightly higher molecular mass than 52 kDa (-.53 kDa) was easily detectable in the cell extract. The 52 kDa protein seems to be the mature precursor of VEGF-2. Based on molecular mass, the 30 and 27 kDa proteins should represent proteolytic cleavage products of the 52 kDa protein. The absence of a cleaved product (or products) in the cell extract of insect (Fig. 4A, lane 3 ) and mammalian cells (Fig. 3) indicates that the cleavage occurred upon secretion.
When analyzed on a nonreducing gel, the cleaved forms of VEGF-2 disappeared and higher levels of protein with the molecular weight close to the precursor appeared.
Proteins with approximately two-and fourfold the molecular weight of the precursor also appeared from VEGF-2 medium (lane 10). These proteins are not present in control medium (lanes 2, 8) from cells infected with nonrecombinant baculovirus.
This result shows that VEGF-2 is secreted and cleaved and that these proteins can form multimenc complex via a disulfide bridge (or bridges).
To obtain pure recombinant VEGF-2 protein, conditioned medium of cells infected with VEGF-2 recombinant baculovirus was purified through ionexchange and hydrophobic interaction chromatography. As shown in Fig. 4B , the 30 and the 27 kDa, but not the putative precursor, proteins were copurified by this procedure.
When analyzed by SDS-PAGE under nonreducing conditions (Fig. 4B) , the 30 and 27 kDa proteins observed under reducing condition (lane 2) disappeared, whereas a 52 and 90 kDa bands absent under reducing condition appeared. This indicates that the two cleaved products formed heterodimer via a disulfide bridge (or bridges). The purified proteins were subjected to the amino-terminal sequencing.
The sequencing result showed that the 30 kDa protein is the amino-terminal portion of cleaved VEGF-2 and its amino termini began with the 32nd (FESGLD.. .) amino acid. The 27 kDa protein is the carboxy-terminal portion of cleaved VEGF-2, whose amino termini began with 238th amino acid residue (SLPATL...) from the initiation codon (as indicated in Fig. 1 The increase was threefold at a 100 ng/ml concentration.
An increase was also observed at the cell number (data not shown). As positive controls, both bFGF and VEGF stimulated about a sixfold increase at a 50 ng/ml concentration. The slope of the dose-response curves by both positive controls are steeper than that of VEGF-2. Thus, VEGF-2 is not as potent as bFGF and VEGF in stimulating HUVEC proliferation.
The stimulatory effect of VEGF-2 on proliferation is not affected by 8 units/ml of heparin (data not shown). VEGF-2 did not stimulate proliferation of fibroblast cells (data not shown). These data demonstrate that VEGF-2 is capable of stimulating the growth of vascular endothelial cells from human umbilical vein.
VEGF-2 inhibits proliferation of vascular smooth muscle cells induced by PDGF, but not by fetal bovine serum Since VEGF-2 mRNA is abundant in aortic smooth muscle cells, the ability of VEGF-2 to stimulate proliferation of HAoSMC was examined using the VEGF-2 proteins purified from baculovirus.
VEGF-2 was also examined for synergistic and inhibitory effects on the proliferation of HAoSMC stimulated by both PDGF and 5% FBS. Although no stimulatory or synergistic effect on HAoSMC proliferation was detected with VEGF-2 (data not shown), an inhibitory effect on HAoSMC proliferation induced by PDGF is apparent. As shown in Fig. 6A , the same batch of VEGF-2 used in Fig. 5 inhibited HAoSMC proliferation in a dosedependent manner.
The optimal concentration of VEGF-2 for inhibition was 50 ng/ml, at which HAoSMC proliferation was inhibited by nearly 70%. VEGF-2 has no inhibitory effect on HAoSMC proliferation induced by 5% FBS (Fig. 6B) . As a negative control, the active protein of a new member in the FGF gene family purified from baculovirus had no inhibitory effect in the same concentration range (data not shown). This result indicates that VEGF-2 selectively inhibits PDGF-induced vascular smooth muscle cell proliferation. While this manuscript was in preparation, VEGF-C and VRP were described as the ligand for the F1t4 and KDR receptor tyrosine kinases (8, 9). The amino acid sequence of VRP is identical with VEGF-2 coding sequence except that the third residue located within the signal peptide.
VEGF-C represents partial sequence of VRP and VEGF-2. Our study confirmed the mitogenic activity of VEGF-2/VRP on vascular endothelial cells using HUVEC; more important, it demonstrated its selective inhibitory activity on HAoSMC proliferation induced by PDGF. Similar to the study of VEGF-C (8), we observed higher expression of VEGF-2/VEGF-C mRNA in several tissues rich in vasculature. We extended this observation by showing abundant expression of VEGF-2 mRNA in vascular smooth muscle cells. In HUVEC, a much lower level of VEGF-2 mRNA was detected (Fig. 2C) One day later, the amount of cell proliferation was determined by BrdU incorporation.
The fold of BrdU incorporation is calculated based on the baseline control, which is given a value of 1.
pattern of VEGF (30) . The similarities of VEGF-2 and VEGF in sequence and mRNA distribution suggest that VEGF-2 may function as a heterodimer with VEGF in vivo.
The amino-terminal sequencing of the 27 kDa product of VEGF-2 reveals the putative cleavage site. The amino-terminal portion of VEGF-2 resulting from the cleavage contains the conserved functional domain, but no heparin binding domain; this portion is more similar to VEGFI2I at overall structure. The carboxy-terminal portion of VEGF-2 contains a region homologous to VEGF at the alternatively spliced exon 7 that contributes to the heparin binding ability to a lesser extent than exon 6 (7). The carboxy-terminal portion of VEGF-2 contains four CXCXC repeats typically found in balbiani ring proteins that constitute silk-like threads (31, 32) . These repeats in VEGF-2 may play a role in interactions with extracelluar matrix.
Since the amino-terminal portion of VEGF-2 is linked to the carboxy-terminal portion by disulfide bonds, the carboxy-terminal portion may play a novel regulatory role on the biochemical or biological activity of the amino-terminal portion. The less potent mitogenic activty of VEGF-2 vs. VEGF on HUVEC is similar to that of VRP (i.e., VEGF-2 or VEGF-C) in human lung microvascular endothelial cells (9). It is possible that there are fewer receptors for VEGF-2 (VRP) or the receptor affinity is lower in these cell types compared with the receptor for VEGF. Since VEGF-2 has a unique carboxyl terminus portion that is proteolytically cleaved, it is also conceivable that the carboxyl terminus portion of VEGF-2 that is covalently linked to the amino-terminal portion of VEGF-2 may have reduced the affin-
